BioSpace News Archive

Health Canada is advising Canadians that LinkGlobal Food Inc. in Richmond Hill, Ontario, is recalling unauthorized “Yunnan Baiyao Toothpaste” because it is labelled to contain a prescription drug (tranexamic acid) and may pose serious health risks.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of INGREZZA® (valbenazine) capsules in reducing abnormal movements in adults with tardive dyskinesia (TD), a potentially irreversible and often persistent involuntary movement disorder.

AIDS Healthcare Foundation (AHF) today is calling on Gilead Sciences Inc., one of the largest manufacturers of HIV/AIDS drugs, for a major price reduction on its HIV/AIDS treatment medication Descovy, the drug company’s fixed-dose combination of emtricitabine (FTC) and tenofovir alafenamide (TAF), for its use now also as pre-exposure prophylaxis or PrEP to prevent HIV acquisition in uninfected individuals.

Audentes Therapeutics, Inc. announced it has granted equity awards that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to twenty-one individuals hired by Audentes in September 2019.

The Asia Agri-Tech Expo & Forum 2019 will take place at Taipei Nangang Exhibition Center Hall 1 from October 31 to November 2.

Centers will serve diverse communities with one-stop access to multiple healthcare services and offer onsite answers for insurance questions

Oyster Point Pharma, Inc. announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of shares of its common stock.

Class-action law firm urges SDC investors who have suffered losses to learn their shareholder rights

Innovent Biologics, Inc. announced that it has agreed to place 97,000,000 new shares at HK$24.60 with overwhelming subscription from well-known international and local investors.

Griffin-American Healthcare REIT III, Inc. announced that its board of directors has approved an updated estimated per share net asset value of its common stock of $9.40 calculated as of June 30, 2019.